Arbutus Biopharma (ABUS) Stock Forecast, Price Target & Predictions
ABUS Stock Forecast
Arbutus Biopharma stock forecast is as follows: an average price target of $8.50 (represents a 108.33% upside from ABUS’s last price of $4.08) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ABUS Price Target
The average price target for Arbutus Biopharma (ABUS) is $8.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.50 to $8.50. This represents a potential 108.33% upside from ABUS's last price of $4.08.
ABUS Analyst Ratings
According to 3 Wall Street analysts, Arbutus Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for ABUS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Arbutus Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 17, 2022 | Ed Arce | H.C. Wainwright | $8.50 | $3.02 | 181.46% | 108.33% |
The latest Arbutus Biopharma stock forecast, released on Mar 17, 2022 by Ed Arce from H.C. Wainwright, set a price target of $8.50, which represents a 181.46% increase from the stock price at the time of the forecast ($3.02), and a 108.33% increase from ABUS last price ($4.08).
Arbutus Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $4.08 | $4.08 | $4.08 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Arbutus Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arbutus Biopharma's last price of $4.08. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | Jefferies | Buy | Buy | Hold |
| Jun 28, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Mar 17, 2022 | H.C. Wainwright | Buy | Buy | Hold |
| Feb 02, 2022 | Jefferies | - | Buy | Upgrade |
Arbutus Biopharma's last stock rating was published by Jefferies on Sep 05, 2024. The company gave ABUS a "Buy" rating, the same as its previous rate.
Arbutus Biopharma Financial Forecast
Arbutus Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $2.15M | $4.66M | $4.65M | $6.69M | $6.25M | $5.95M | $14.24M | $12.58M | $3.21M | $3.34M | $2.33M | $2.11M | $2.39M | $1.52M | $1.51M | $1.49M | $1.62M | $3.06M | $653.00K | $679.00K | $1.44M | $235.00K |
| Avg Forecast | $1.39M | $1.75M | $1.86M | $1.85M | $1.95M | $1.86M | $1.77M | $2.71M | $4.78M | $4.75M | $6.18M | $6.04M | $6.18M | $9.37M | $6.77M | $4.37M | $2.88M | $2.39M | $2.12M | $3.30M | $2.03M | $1.70M | $1.80M | $1.30M | $1.42M | $5.28M | $786.75K | $1.24M | $1.56M | $269.56K |
| High Forecast | $2.01M | $2.54M | $2.70M | $2.68M | $2.83M | $1.89M | $2.56M | $3.94M | $4.82M | $6.90M | $8.97M | $8.76M | $8.96M | $13.61M | $8.40M | $5.42M | $3.58M | $2.97M | $2.63M | $4.10M | $2.53M | $2.12M | $2.23M | $1.61M | $1.76M | $6.55M | $976.88K | $1.54M | $1.87M | $323.47K |
| Low Forecast | $1.04M | $1.32M | $1.40M | $1.39M | $1.47M | $1.82M | $1.33M | $2.04M | $4.74M | $3.58M | $4.65M | $4.54M | $4.65M | $7.06M | $5.83M | $3.76M | $2.48M | $2.06M | $1.82M | $2.85M | $1.75M | $1.47M | $1.55M | $1.12M | $1.22M | $4.54M | $677.48K | $1.06M | $1.24M | $215.65K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | 0.45% | 0.98% | 0.75% | 1.11% | 1.01% | 0.63% | 2.10% | 2.88% | 1.11% | 1.40% | 1.10% | 0.64% | 1.17% | 0.89% | 0.84% | 1.15% | 1.14% | 0.58% | 0.83% | 0.55% | 0.92% | 0.87% |
Arbutus Biopharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $2.71M, with a low forecast of $2.04M, and a high forecast of $3.94M. ABUS's average Quarter revenue forecast represents a 26.54% increase compared to the company's last Quarter revenue of $2.15M (Dec 23).
Arbutus Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | $-20.52M | $-21.56M | $-18.39M | $-15.87M | $-20.01M | $-16.56M | $-13.12M | $-10.22M | $-20.33M | $-17.95M | $-18.19M | $-15.17M | $-15.76M | $-17.19M | $-12.49M | $-12.32M | $-23.15M | $-93.55M | $-22.81M | $-22.73M | $-16.72M | $-18.25M |
| Avg Forecast | $-1.39M | $-1.75M | $-1.86M | $-1.85M | $-1.95M | $-1.86M | $-1.77M | $-2.71M | $-4.78M | $-4.75M | $-6.18M | $-6.04M | $-6.18M | $-19.74M | $-6.77M | $-14.19M | $-2.88M | $-2.39M | $-2.12M | $-16.48M | $-2.03M | $-1.70M | $-1.80M | $-14.70M | $-1.42M | $-5.28M | $-786.75K | $-13.28M | $-18.01M | $-20.59M |
| High Forecast | $-1.04M | $-1.32M | $-1.40M | $-1.39M | $-1.47M | $-1.82M | $-1.33M | $-2.04M | $-4.74M | $-3.58M | $-4.65M | $-4.54M | $-4.65M | $-15.80M | $-5.83M | $-11.36M | $-2.48M | $-2.06M | $-1.82M | $-13.19M | $-1.75M | $-1.47M | $-1.55M | $-11.76M | $-1.22M | $-4.54M | $-677.48K | $-10.63M | $-14.41M | $-16.47M |
| Low Forecast | $-2.01M | $-2.54M | $-2.70M | $-2.68M | $-2.83M | $-1.89M | $-2.56M | $-3.94M | $-4.82M | $-6.90M | $-8.97M | $-8.76M | $-8.96M | $-23.69M | $-8.40M | $-17.03M | $-3.58M | $-2.97M | $-2.63M | $-19.78M | $-2.53M | $-2.12M | $-2.23M | $-17.65M | $-1.76M | $-6.55M | $-976.88K | $-15.94M | $-21.61M | $-24.71M |
| Surprise % | - | - | - | - | - | - | - | - | 4.29% | 4.54% | 2.98% | 2.63% | 3.24% | 0.84% | 1.94% | 0.72% | 7.05% | 7.51% | 8.59% | 0.92% | 7.75% | 10.09% | 6.95% | 0.84% | 16.29% | 17.73% | 28.99% | 1.71% | 0.93% | 0.89% |
undefined analysts predict ABUS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Arbutus Biopharma's previous annual EBITDA (undefined) of $NaN.
Arbutus Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 17 |
| Net Income | - | - | - | - | - | - | - | - | $-19.31M | $-20.10M | $-17.09M | $-15.46M | $-22.91M | $-17.32M | $-14.28M | $-15.77M | $-21.88M | $-19.16M | $-19.39M | $-16.38M | $-17.04M | $-18.75M | $-14.09M | $-13.86M | $-24.65M | $-82.50M | $-23.32M | $-23.25M | $-17.43M | $-18.63M |
| Avg Forecast | $-16.45M | $-15.51M | $-15.98M | $-15.51M | $-16.17M | $-17.68M | $-18.05M | $-20.68M | $-17.40M | $-21.06M | $-21.06M | $-25.57M | $-25.20M | $-21.07M | $-23.32M | $-20.69M | $-35.73M | $-44.75M | $-42.31M | $-17.81M | $-41.64M | $-40.62M | $-45.13M | $-16.54M | $-68.07M | $-49.83M | $-70.05M | $-13.59M | $-18.77M | $-21.02M |
| High Forecast | $-11.16M | $-10.53M | $-10.84M | $-10.53M | $-10.97M | $-14.14M | $-12.25M | $-14.03M | $-14.80M | $-14.29M | $-14.29M | $-17.35M | $-17.10M | $-16.86M | $-19.11M | $-16.55M | $-29.28M | $-36.67M | $-34.67M | $-14.24M | $-34.12M | $-33.28M | $-36.98M | $-13.24M | $-55.78M | $-40.83M | $-57.40M | $-10.87M | $-15.02M | $-16.81M |
| Low Forecast | $-26.11M | $-24.62M | $-25.37M | $-24.62M | $-25.67M | $-19.44M | $-28.65M | $-32.83M | $-19.99M | $-33.42M | $-33.42M | $-40.59M | $-39.99M | $-25.29M | $-30.64M | $-24.83M | $-46.95M | $-58.81M | $-55.60M | $-21.37M | $-54.72M | $-53.38M | $-59.31M | $-19.85M | $-89.46M | $-65.49M | $-92.05M | $-16.30M | $-22.52M | $-25.22M |
| Surprise % | - | - | - | - | - | - | - | - | 1.11% | 0.95% | 0.81% | 0.60% | 0.91% | 0.82% | 0.61% | 0.76% | 0.61% | 0.43% | 0.46% | 0.92% | 0.41% | 0.46% | 0.31% | 0.84% | 0.36% | 1.66% | 0.33% | 1.71% | 0.93% | 0.89% |
Arbutus Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ABUS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Arbutus Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 17 |
| SG&A | - | - | - | - | - | - | - | - | $5.10M | $5.84M | $5.98M | $5.55M | $4.25M | $3.49M | $5.20M | $4.89M | $4.70M | $4.15M | $4.45M | $3.85M | $3.54M | $4.07M | $3.57M | $3.55M | $1.88M | $3.25M | $8.19M | $4.41M | $3.67M | $4.33M |
| Avg Forecast | $2.29M | $2.89M | $3.07M | $3.05M | $3.22M | $3.07M | $2.92M | $4.48M | $7.90M | $7.84M | $10.20M | $9.97M | $10.20M | $4.56M | $11.18M | $7.21M | $4.76M | $3.95M | $3.50M | $5.46M | $3.36M | $2.81M | $2.97M | $2.15M | $2.35M | $8.71M | $1.30M | $2.04M | $2.57M | $445.14K |
| High Forecast | $3.33M | $4.19M | $4.46M | $4.43M | $4.67M | $3.12M | $4.23M | $6.51M | $7.95M | $11.39M | $14.81M | $14.47M | $14.80M | $5.47M | $13.88M | $8.96M | $5.91M | $4.90M | $4.34M | $6.78M | $4.17M | $3.49M | $3.69M | $2.67M | $2.91M | $10.82M | $1.61M | $2.54M | $3.08M | $534.16K |
| Low Forecast | $1.72M | $2.17M | $2.31M | $2.30M | $2.42M | $3.00M | $2.20M | $3.37M | $7.83M | $5.90M | $7.68M | $7.50M | $7.68M | $3.65M | $9.62M | $6.21M | $4.10M | $3.40M | $3.01M | $4.70M | $2.89M | $2.42M | $2.56M | $1.85M | $2.02M | $7.50M | $1.12M | $1.76M | $2.06M | $356.11K |
| Surprise % | - | - | - | - | - | - | - | - | 0.65% | 0.74% | 0.59% | 0.56% | 0.42% | 0.77% | 0.47% | 0.68% | 0.99% | 1.05% | 1.27% | 0.71% | 1.05% | 1.45% | 1.20% | 1.66% | 0.80% | 0.37% | 6.30% | 2.16% | 1.43% | 9.72% |
Arbutus Biopharma's average Quarter SG&A projection for Mar 24 is $4.48M, based on 1 Wall Street analysts, with a range of $3.37M to $6.51M. The forecast indicates a -12.13% fall compared to ABUS last annual SG&A of $5.10M (Dec 23).
Arbutus Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 17 |
| EPS | - | - | - | - | - | - | - | - | $-0.11 | $-0.12 | $-0.00 | $-0.10 | $-0.15 | $-0.11 | $-0.10 | $-0.11 | $-0.22 | $-0.24 | $-0.23 | $-0.21 | $-0.18 | $-0.27 | $-0.25 | $-0.25 | $-0.36 | $-1.50 | $-0.46 | $-0.47 | $-0.36 | $-0.34 |
| Avg Forecast | $-0.09 | $-0.08 | $-0.09 | $-0.08 | $-0.09 | $-0.09 | $-0.10 | $-0.11 | $-0.09 | $-0.11 | $-0.11 | $-0.14 | $-0.13 | $-0.13 | $-0.12 | $-0.16 | $-0.19 | $-0.24 | $-0.23 | $-0.23 | $-0.22 | $-0.22 | $-0.24 | $-0.31 | $-0.36 | $-0.27 | $-0.37 | $-0.32 | $-0.42 | $-0.44 |
| High Forecast | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.08 | $-0.07 | $-0.07 | $-0.08 | $-0.08 | $-0.08 | $-0.09 | $-0.09 | $-0.09 | $-0.10 | $-0.13 | $-0.16 | $-0.20 | $-0.18 | $-0.19 | $-0.18 | $-0.18 | $-0.20 | $-0.26 | $-0.30 | $-0.22 | $-0.31 | $-0.26 | $-0.34 | $-0.35 |
| Low Forecast | $-0.14 | $-0.13 | $-0.13 | $-0.13 | $-0.14 | $-0.10 | $-0.15 | $-0.17 | $-0.11 | $-0.18 | $-0.18 | $-0.22 | $-0.21 | $-0.20 | $-0.16 | $-0.21 | $-0.25 | $-0.31 | $-0.30 | $-0.30 | $-0.29 | $-0.28 | $-0.32 | $-0.41 | $-0.48 | $-0.35 | $-0.49 | $-0.42 | $-0.50 | $-0.53 |
| Surprise % | - | - | - | - | - | - | - | - | 1.19% | 1.07% | 0.00% | 0.70% | 1.12% | 0.86% | 0.77% | 0.69% | 1.16% | 1.01% | 1.02% | 0.91% | 0.82% | 1.25% | 1.04% | 0.80% | 1.01% | 5.66% | 1.23% | 1.46% | 0.86% | 0.77% |
According to undefined Wall Street analysts, Arbutus Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ABUS previous annual EPS of $NaN (undefined).
Arbutus Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VBIV | VBI Vaccines | $0.07 | $5.00 | 7042.86% | Strong Buy |
| ADAP | Adaptimmune Therapeutics | $1.05 | $2.83 | 169.52% | Buy |
| ABUS | Arbutus Biopharma | $4.08 | $8.50 | 108.33% | Buy |
| AFMD | Affimed | $4.07 | $7.50 | 84.28% | Buy |
| CRVS | Corvus Pharmaceuticals | $5.50 | $7.00 | 27.27% | Buy |
| ADMA | ADMA Biologics | $18.71 | $9.25 | -50.56% | Buy |
ABUS Forecast FAQ
Is Arbutus Biopharma a good buy?
Yes, according to 3 Wall Street analysts, Arbutus Biopharma (ABUS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ABUS's total ratings.
What is ABUS's price target?
Arbutus Biopharma (ABUS) average price target is $8.5 with a range of $8.5 to $8.5, implying a 108.33% from its last price of $4.08. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Arbutus Biopharma stock go up soon?
According to Wall Street analysts' prediction for ABUS stock, the company can go up by 108.33% (from the last price of $4.08 to the average price target of $8.5), up by 108.33% based on the highest stock price target, and up by 108.33% based on the lowest stock price target.
Can Arbutus Biopharma stock reach $6?
ABUS's average twelve months analyst stock price target of $8.5 supports the claim that Arbutus Biopharma can reach $6 in the near future.
What are Arbutus Biopharma's analysts' financial forecasts?
Arbutus Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $8.29M (high $11.23M, low $6.66M), average EBITDA is $-8.289M (high $-6.656M, low $-11.225M), average net income is $-72.584M (high $-51.396M, low $-107M), average SG&A $13.69M (high $18.54M, low $10.99M), and average EPS is $-0.386 (high $-0.273, low $-0.567). ABUS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.85M (high $9.94M, low $5.15M), average EBITDA is $-6.846M (high $-5.153M, low $-9.937M), average net income is $-63.464M (high $-43.06M, low $-101M), average SG&A $11.3M (high $16.41M, low $8.51M), and average EPS is $-0.338 (high $-0.229, low $-0.536).
Did the ABUS's actual financial results beat the analysts' financial forecasts?
Based on Arbutus Biopharma's last annual report (Dec 2023), the company's revenue was $18.14M, which missed the average analysts forecast of $21.75M by -16.59%. Apple's EBITDA was $-78.103M, beating the average prediction of $-21.75M by 259.10%. The company's net income was $-72.849M, missing the average estimation of $-85.092M by -14.39%. Apple's SG&A was $22.48M, missing the average forecast of $35.92M by -37.42%. Lastly, the company's EPS was $-0.0004, missing the average prediction of $-0.453 by -99.91%. In terms of the last quarterly report (Dec 2023), Arbutus Biopharma's revenue was $2.14M, missing the average analysts' forecast of $4.78M by -55.17%. The company's EBITDA was $-20.52M, beating the average prediction of $-4.785M by 328.86%. Arbutus Biopharma's net income was $-19.312M, beating the average estimation of $-17.397M by 11.01%. The company's SG&A was $5.1M, missing the average forecast of $7.9M by -35.44%. Lastly, the company's EPS was $-0.11, beating the average prediction of $-0.0925 by 18.90%